Leonard Zehr, Author at BioTuesdays

Developments

Profound Medical’s TULSA-PRO front and center at AUA2022

The American Urological Association’s 2022 annual meeting featured multiple clinical presentations and product demonstrations of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO to effectively and safely ablate...

May 18, 2022

Feature

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

Closely-held Lanier Biotherapeutics is pioneering a first-in-class Type 2 and non- Type2 anti-inflammatory biologic, LNR 125, as a new candidate targeting treatments commonly associated with Type 2 inflammation like...

May 17, 2022

Markets

HCW cuts Pulse Biosciences to neutral; withdraws PT

H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” without a price target, reflecting a lack of clarity about Pulse’s commercial timelines and funding availability. The stock closed at $1...

May 13, 2022

Feature

Qualigen advancing platform technologies in therapeutics and diagnostics

Backed by a commercial diagnostics business, Qualigen Therapeutics (NASDAQ:QLGN) has broadened its focus to developing platform therapeutics for cancer with potential orphan drug designation.

May 10, 2022

Developments

iBio demonstrates efficacy of an IL-2 sparing anti-CD25 antibody in cancer

iBio (NYSE American:IBIO) is presenting a poster on IBIO-101, its monoclonal antibody candidate for the treatment of solid tumors, at Frontiers in Cancer Immunotherapy 2022 in New York May 9-11. Preclinical evaluation...

May 9, 2022

Markets

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

May 5, 2022

Developments

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Rani Therapeutics (NASDAQ:RANI) took top honors for its RaniPill capsule in the health category of Fast Company‘s 2022 World Changing Ideas. The RaniPill capsule is about the size of a standard fish oil pill...

May 3, 2022

Feature

Talking mental health with Chris Wang of Shimmer

As co-founder and CEO of Shimmer, a provider of a science-backed process to reduce stress and anxiety, Chris Wang took an early interest in social impact consulting at her first job with Bain & Co. But a close family...

May 3, 2022

Feature

Claritas Pharmaceuticals transforming nitric oxide therapy

Claritas Pharmaceuticals (TSXV:CLAS; OTC:CLAZF) is developing R-107, a liquid drug candidate that may hold the key to transforming nitric oxide therapy from its current gaseous inhalation method of delivery to...

April 26, 2022

Markets

BTIG ups Biodesix PT to $17 from $10

BTIG raised its price target for Biodesix (NASDAQ:BDSX) to $17 from $10, saying “performance this year should restore investor confidence.” The stock closed at $1.61 on April 14. Analyst Sung Ji Nam writes that the...

April 15, 2022

Author - Leonard Zehr

Profound Medical’s TULSA-PRO front and center at AUA2022

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

HCW cuts Pulse Biosciences to neutral; withdraws PT

Qualigen advancing platform technologies in therapeutics and diagnostics

iBio demonstrates efficacy of an IL-2 sparing anti-CD25 antibody in cancer

Analysts downgrade Amarin; PTs cut to $3

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Talking mental health with Chris Wang of Shimmer

Claritas Pharmaceuticals transforming nitric oxide therapy

BTIG ups Biodesix PT to $17 from $10

General

More